A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC

Inclusion Criteria: * ECOG PS of 0 or 1 * Histologically confirmed NSCLC * Adequate amount of tumor (archived or fresh) for biomarker evaluation * Received one to two regimens of chemotherapy (with at least one platinum-containing) * Serum creatinine of less than 1.0 mg/dL or a 24 hour creatinine clearance of greater than 60 mL/min * Stable control of blood pressure on agents other than calcium channel blockers * Women of child-bearing potential must avoid pregnancy or maintain adequate contraception * Must be able to swallow pills and take the medications at the same time every day on an empty stomach Exclusion Criteria: * ECOG PS 2 or greater * Women unwilling to avoid pregnancy or use adequate contraception * Symptomatic brain metastases * Recent history of TIA, CVA, or thrombotic/thromboembolic event (within 6 months) * History of hemoptysis greater than 10 mL/day * Significant cardiovascular disease * Uncontrolled diarrhea, Crohn's disease, ulcerative colitis, or any malabsorptive disease * History of use of other TKIs * Uncontrolled hypertension * HIV+